Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

62.50p
   
  • Change Today:
    -0.50p
  • 52 Week High: 71.50
  • 52 Week Low: 49.00
  • Currency: UK Pounds
  • Shares Issued: 70.57m
  • Volume: 2,827
  • Market Cap: £44.11m
  • RiskGrade: 22

Tissue Regenix makes first delivery of 'OrthoPure XT'

By Josh White

Date: Wednesday 02 Dec 2020

LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix announced on Wednesday that its first delivery of 'OrthoPure XT' has taken place, with additional shipments expected in early 2021.
The AIM-traded firm described OrthoPure XT as a decellularised porcine tendon, developed using its patented 'dCELL' technology.

It was granted CE-mark approval in June for the reconstruction of knee ligaments to restore function and stability.

In August, the company announced its first distribution agreement, focussed on the UK market, with an unnamed speciality supplier of orthopaedic and biologic products.

The group said it had since targeted key European markets, including securing an additional distribution partner in Poland.

Tissue Regenix said it was currently engaged in a number of discussions with potential partners in other geographies.

"Our plan is to establish an initial distribution network for OrthoPure XT and expand as procedural levels return," said chief executive officer Daniel Lee.

"This will be a key product for the Group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market.

"It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020."

At 0946 GMT, shares in Tissue Regenix were down 2.25% at 0.52p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 62.50p
Change Today -0.50p
% Change -0.79 %
52 Week High 71.50
52 Week Low 49.00
Volume 2,827
Shares Issued 70.57m
Market Cap £44.11m
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.8% below the market average41.8% below the market average41.8% below the market average41.8% below the market average41.8% below the market average
61.9% below the sector average61.9% below the sector average61.9% below the sector average61.9% below the sector average61.9% below the sector average
Price Trend
75.89% above the market average75.89% above the market average75.89% above the market average75.89% above the market average75.89% above the market average
62.07% above the sector average62.07% above the sector average62.07% above the sector average62.07% above the sector average62.07% above the sector average
Income Not Available
Growth
18.07% above the market average18.07% above the market average18.07% above the market average18.07% above the market average18.07% above the market average
11.11% above the sector average11.11% above the sector average11.11% above the sector average11.11% above the sector average11.11% above the sector average

TRX Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
15:40 4 @ 63.00p
15:40 10 @ 62.00p
15:40 75 @ 63.00p
15:40 3 @ 62.00p
15:40 10 @ 62.00p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page